Andrews, David

Biography

Dr. David Andrews is director of, and senior scientist in Biological Sciences at Sunnybrook Research Institute (SRI) and a Tier 1 Canada Research Chair. His research comprises, the molecular mechanisms by which Bcl-2 family proteins regulate apoptosis, the assembly of proteins into the endoplasmic reticulum membrane, high-content screening and development of new microscopes for fluorescence lifetime imaging microscopy (FLIM) and hyperspectral imaging. Dr. Andrews uses fluorescence spectroscopy and fluorescence spectroscopic microscopy to study interactions between proteins in membranes using purified proteins, and in live cells. He has established a facility for image-based high-content cellular analysis at SRI that includes the most sophisticated FLIM instruments available in the world. His lab has discovered small molecules that have application to cancer and regenerative medicine. Dr. Andrews has collaborated with a number of pharmaceutical companies including Abbott, ABBVIE, Eli Lilly, Genentech, and others and is a member of scientific advisory boards including at the Max Plank Institute. He is developing a new generation automated high-speed hyperspectral FLIM confocal and new software for automated analysis of fluorescence micrographs of cells. Automated microscopy and machine learning tools are being applied to develop new personalized medicine approaches for diseases such as chronic lymphocytic leukemia, and to study protein binding to membranes. The imaging research done in Dr. David Andrews’ lab recently culminated in the establishment of a new, $9-million image-based screening facility at Sunnybrook Research Institute. Dr. David Andrews is director of, and senior scientist in Biological Sciences at Sunnybrook Research Institute (SRI) and a Tier 1 Canada Research Chair. His research comprises, the molecular mechanisms by which Bcl-2 family proteins regulate apoptosis, the assembly of proteins into the endoplasmic reticulum membrane, high-content screening and development of new microscopes for fluorescence lifetime imaging microscopy (FLIM) and hyperspectral imaging. Dr. Andrews uses fluorescence spectroscopy and fluorescence spectroscopic microscopy to study interactions between proteins in membranes using purified proteins, and in live cells. He has established a facility for image-based high-content cellular analysis at SRI that includes the most sophisticated FLIM instruments available in the world. His lab has discovered small molecules that have application to cancer and regenerative medicine. Dr. Andrews has collaborated with a number of pharmaceutical companies including Abbott, ABBVIE, Eli Lilly, Genentech, and others and is a member of scientific advisory boards including at the Max Plank Institute. He is developing a new generation automated high-speed hyperspectral FLIM confocal and new software for automated analysis of fluorescence micrographs of cells. Automated microscopy and machine learning tools are being applied to develop new personalized medicine approaches for diseases such as chronic lymphocytic leukemia, and to study protein binding to membranes. The imaging research done in Dr. David Andrews’ lab recently culminated in the establishment of a new, $9-million image-based screening facility at Sunnybrook Research Institute.

Research Interest

cancer research